logo

For the Inventor, By the Inventor

Munich, Germany

Juno Therapeutics Gmbh


USPTO Granted Patents = 66



Trademarks = 8

Forward Citations = 124

Loading Chart...
Loading Chart...

140 inventors (with patents filed for the assignee):

goldMedal Mark J Gilbert (7 out of 20 patents)

silverMedal He Li (7 out of 7 patents)

bronzeMedal Steven M Shamah (7 out of 11 patents)

4.  Csaba Pazmany (7 out of 10 patents)

5.  Jui Dutta-Simmons (7 out of 7 patents)

6.  Yan Chen (7 out of 50 patents)

7.  Christopher Glen Ramsborg (6 out of 6 patents)

8.  Tina Albertson (5 out of 5 patents)

9.  Chris Ramsborg (5 out of 5 patents)

10.  Mark L Bonyhadi (5 out of 13 patents)

11.  Pascal Beauchesne (5 out of 5 patents)

12.  Lothar Germeroth (5 out of 8 patents)

13.  Christian Stemberger (5 out of 7 patents)

14.  Blythe D Sather (5 out of 5 patents)

15.  Collin Hauskins (5 out of 5 patents)


Core Competencies:
Machine Learning Methods
Chimeric Antigen Receptors
Cell Surface Glycosylation
Immunomodulatory Polypeptides
Genetically Engineered Cells
Adoptive Cell Therapy
Tumor Burden Assessment
T Cell Modulation
Therapeutic Compositions
Epigenetic Analysis
Immune Cell Modulation
Antibody Engineering

66 patents:

1. 12444491 - Machine learning methods for classifying cells (2025-10-14),
2. 12435120 - Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods (2025-10-07),
3. 12428486 - Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides (2025-09-30),
4. 12379375 - Methods for assessing cell surface glycosylation (2025-08-05),
5. 12366580 - Methods for mass spectrometry analysis of engineered cell compositions (2025-07-22),
6. 12304935 - Immunomodulatory polypeptides and related compositions and methods (2025-05-20),
7. 12296010 - Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy (2025-05-13),
8. 12268741 - Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) (2025-04-08),
9. 12264371 - Methods and reagents for assessing the presence or absence of replication competent virus (2025-04-01),
10. 12263190 - Methods and combinations for treatment and T cell modulation (2025-04-01),
11. 12258580 - Process for generating therapeutic compositions of engineered cells (2025-03-25),
12. 12215348 - Methods for producing genetically engineered cell compositions and related compositions (2025-02-04),
13. 12208137 - Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy (2025-01-28),
14. 12193994 - Combination of a cell therapy and a gamma secretase inhibitor (2025-01-14),
15. 12168027 - Methods associated with tumor burden for assessing response to a cell therapy (2024-12-17),
Juno Therapeutics GmbH is a biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. They use advanced CAR-T cell technology to reprogram the body's immune system to recognize and combat cancer cells. Juno Therapeutics aims to provide safer and more effective treatments for patients suffering from various types of cancers.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
66 Patents

#63 in W-8000 Munich

#878 in Germany

#10,731 in the World

...
Munich, Germany

Juno Therapeutics Gmbh

Forward Citations = 124

140 inventors:

goldMedal Mark J Gilbert (7 out of 20 patents)

silverMedal He Li (7 out of 7 patents)

bronzeMedal Steven M Shamah (7 out of 11 patents)

4.  Csaba Pazmany (7 out of 10 patents)

5.  Jui Dutta-Simmons (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com
Loading…